# A Study to Evaluate the Effectiveness and Safety Initiation and Titration of Insulin Glargine (U300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus (T2DM) Controlled on Oral Antidiabetic Drug Treatment in Turkey

Study · id `cardio:ct-nct02954692` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02954692](<https://clinicaltrials.gov/study/NCT02954692>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02954692

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 112 participants.

## Technical summary

Registry record NCT02954692. Allocation not applicable; no masking; primary purpose treatment. Start 2016-11-30 (registry gives no type); primary completion 2017-12-22 (actual). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 112 participants (enrolled count; ClinicalTrials.gov record NCT02954692, source copy `cardio:ctgov-nct02954692-2019-01-14`, retrieved 2026-10-26)
- Start date: 2016-11-30 (registry gives no type) (ClinicalTrials.gov record NCT02954692, source copy `cardio:ctgov-nct02954692-2019-01-14`, retrieved 2026-10-26)
- Primary completion: 2017-12-22 (actual) (ClinicalTrials.gov record NCT02954692, source copy `cardio:ctgov-nct02954692-2019-01-14`, retrieved 2026-10-26)
- Completion: 2017-12-22 (actual) (ClinicalTrials.gov record NCT02954692, source copy `cardio:ctgov-nct02954692-2019-01-14`, retrieved 2026-10-26)
- Countries: Türkiye (ClinicalTrials.gov record NCT02954692, source copy `cardio:ctgov-nct02954692-2019-01-14`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02954692-2019-01-14`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study to Evaluate the Effectiveness and Safety Initiation and Titration of Insulin Glargine (U300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus (T2DM) Controlled on Oral Antidiabetic Drug Treatment in Turkey
- Acronym: EASE
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): INSULIN GLARGINE (U300)
- Intervention (Drug): metformin
- Intervention (Drug): sulfonylurea
- Intervention (Drug): meglitinides
- Intervention (Drug): thiazolidinediones
- Intervention (Drug): alpha-glucosidase inhibitors
- Intervention (Drug): GLP1 Receptor Agonist
- Intervention (Drug): Dipeptidyl peptidase-IV (DPP-IV) inhibitors
- Intervention (Drug): Sodium-glucose transport-2 (SGLT-2) inhibitors
- Lead sponsor: Sanofi
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Sanofi (`cardio:org-sanofi`)

## Provenance

Content hash: 57d0f73f581d77814046498c65c5504f77081739c3b1c6d06d1ffe8fca2f6145
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
